GELSNasdaqPharmaceutical PreparationsFiscal year ends June 30
Gelteq Ltd
Financials through fiscal 2025, year ended Jun 30, 2025Last filing: 20-F on Nov 17, 2025
$0.43−0.02 (-3.50%)
Close on Oct 19, 2026
Ownership
Who owns Gelteq's shares
Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Paul Michael WYNNE | Chief Scientific Officer | – | – | Mar 18, 2026 |
| Bradley Glenn Karp | Head of Sales and Marketing | 500,000 | 4.67% | Mar 18, 2026 |
| Nathan J. Givoni | Chief Executive Officer | 657,087 | 6.13% | Mar 18, 2026 |
| Simon H. Szewach | Director | 338,197 | 3.16% | Mar 18, 2026 |